Ipsen Upgrades Full-Year Guidance After Nine-Month Sales Growth
Ipsen reported sales for the first nine months and third quarter of 2026 and further upgraded its full-year guidance.
PARIS, FRANCE, 22 October 2026 - Ipsen (EURONEXT:IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year-to-date and third quarter of 2026. YTD YTD % Q3 Q3…